Actively Recruiting
Quality of Life Study in Elderly Patients with Low-Grade Non-Hodgkin Lymphoma Receiving Immunotherapy, Immunochemotherapy, or Radiotherapy An Observational Prospective Study by Fondazione Italiana Linfomi
Led by Fondazione Italiana Linfomi - ETS · Updated on 2026-09-11
150
Participants Needed
21
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the quality of life QoL changes in elderly patients with low-grade non-Hodgkin lymphoma during their clinical management. This observational, prospective study aims to identify key factors at diagnosis and during treatment that affect QoL. The study includes patients aged 70 years and older with confirmed indolent B cell non-Hodgkin lymphoma who are starting treatment for the first time. Participants may receive any type of lymphoma treatment as decided by their doctors, including immunotherapy, immunochemotherapy at full or reduced doses, or radiotherapy. All patients undergo a Comprehensive Geriatric Assessment before starting treatment. The study observes QoL at three points before treatment begins, at the end of treatment which can last from 1 to 6 months, and one year after treatment starts. Throughout the study, patients follow their usual clinical care routines, with assessments and response evaluations done as part of standard practice. Quality of life is measured using established questionnaires EORTC-QLQ-C30 and FACT-Lym-LymS. Researchers also track overall survival, progression-free survival, event-free survival, response rates, and safety data over up to 30 months. Participants are involved in routine clinical visits and complete QoL questionnaires at specified times during the study.
CONDITIONS
Brief Title
Quality Of Life On Elderly Patients With Low Grade Non-Hodgkin Lymphoma
Research Team
M
Marina Cesaretti
I
Iolanda De Martino
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here